Yohei Sato

Title: Yohei Sato: Innovator in Immunotherapy

Introduction

Yohei Sato is a prominent inventor based in Palo Alto, CA (US). He has made significant contributions to the field of immunotherapy, particularly in the development of engineered T cells. His innovative work focuses on promoting immune tolerance, which is crucial for various therapeutic applications.

Latest Patents

Yohei Sato holds a patent for "FOXP3 engineered CD4+ T cells for use in treg-based immunotherapy." This patent describes engineered Treg-like cells, specifically CD4T cells, and their application in cellular therapy. The process involves transducing CD4T cells with a lentiviral vector that expresses FOXP3 under a constitutive promoter. The transduced cells exhibit high and persistent levels of FOXP3 and acquire immune suppressive characteristics similar to naturally occurring Treg cells. This advancement has the potential to enhance immunotherapy strategies significantly.

Career Highlights

Throughout his career, Yohei Sato has worked with esteemed institutions, including the Board of Trustees of the Leland Stanford Junior University and Ospedale San Raffaele S.r.l. His work has been instrumental in advancing the understanding and application of T cell engineering in therapeutic contexts.

Collaborations

Yohei Sato has collaborated with notable professionals in his field, including Rosa Bacchetta and Maria Grazia Roncarolo. These collaborations have contributed to the development of innovative approaches in immunotherapy.

Conclusion

In summary, Yohei Sato is a key figure in the field of immunotherapy, with a focus on engineered T cells. His patent and collaborative efforts highlight his commitment to advancing medical science and improving therapeutic outcomes.